1.
Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500–8.
2.
Yeum K-J, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430:97–103.
3.
Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655–73.
4.
Freeman LM, Rush JE, Milbury PE, Blumberg JB. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. J Vet Intern Med. 2005;19:537–41.
5.
Freeman LM, Rush JE, Markwell PJ. Effects of dietary modification in dogs with early chronic valvular disease. J Vet Intern Med. 2006;20:1116–26.
6.
Reimann MJ, Häggström J, Mortensen A, Lykkesfeldt J, Møller JE, Falk T, et al. Biopterin status in dogs with myxomatous mitral valve disease is associated with disease severity and cardiovascular risk factors. J Vet Intern Med. 2014;28:1520–6.
7.
Kovacic P, Somanathan R. Mechanism of anesthetic toxicity: metabolism, reactive oxygen species, oxidative stress, and electron transfer. ISRN Anesthesiol. 2011;1–10. Available from:
http://dx.doi.org/10.5402/2011/402906
.
8.
Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: The relevance to anesthesia practice. Anesth Analg. 2005;101:1275–87.
9.
Volti LG, Murabito P, Attaguile G, Rodella LF, Astuto M, Di Giacomo C, et al. Antioxidant properties of propofol: when oxidative stress sleeps with patients. EXCLI J. 2006;5:25–32. Available from:
https://www.excli.de/vol5/Li_Volti03-06proof.pdf
.
10.
Murphy PG, Myers DS, Davies MJ, Webster NR, Jones JG. The antioxidant potential of propofol (2,6-diisopropyl-phenol). Br J Anaesthes. 1992;68:613–8.
11.
Kharasch ED. Biotransformation of sevoflurane. Anesth Analg. 1995;81:27–38.
12.
Sedlic F, Pravdic D, Ljubkovic M, Marinovic J, Stadnicka A, Bosnjak ZJ. Differences in production of reactive oxygen species and mitochondrial uncoupling as events in the preconditioning signaling cascade between desflurane and sevoflurane. Anesth Analg. 2009;109:405–11.
13.
Popov IN, Lewin G. Photochemiluminescent detection of antiradical activity; IV: testing of lipid-soluble antioxidants. J Biochem Biophys Methods. 1996;31:1–8.
14.
Tomsič K, Nemec Svete A, Nemec A, Domanjko Petrič A, Vovk T, Seliškar A. Influence of sevoflurane or propofol anaesthesia on oxidative stress parameters in dogs with early-stage myxomatous mitral valve degeneration. A preliminary study. Acta Vet-Beograd. 2018;68:32–42.
15.
Naziroǧlu M, Günay C. The levels of some antioxidant vitamins, glutathione peroxidase and lipoperoxidase during the anaesthesia of dogs. Cell Biochem Funct. 1999;17:207–12.
16.
Ceylan BG, Yilmaz F, Eroglu F, Yavuz L, Gulmen S, Vural H. Oxidant and antioxidant activities of different anesthetic techniques. Propofol versus desflurane. Saudi Med J. 2009;30:371–6.
17.
Eroglu F, Yavuz L, Ceylan BG, Yilmaz F, Eroglu E, Delibas N, et al. New volatile anesthetic, desflurane, reduces vitamin E level in blood of operative patients via oxidative stress. Cell Biochem Funct. 2010;28:211–6.
18.
Braz MG, Braz LG, Freire CMM, Lucio LMC, Braz JRC, Tang G, et al. Isoflurane and propofol contribute to increasing the antioxidant status of patients during minor elective surgery: a randomized clinical study. Med (Baltim). 2015;94(31):e1266.
19.
Cavalca V, Colli S, Veglia F, Eligini S, Zingaro L, Squellerio I, et al. Anesthetic propofol enhances plasma gamma-tocopherol levels in patients undergoing cardiac surgery. Anesthesiology. 2008;108:988–97.
20.
El-Bassiouni EA, Abo-Ollo MM, Helmy MH, Ismail S, Ramadan MI. Changes in the defense against free radicals in the liver and plasma of the dog during hypoxia and/or halothane anaesthesia. Toxicology. 1998;128:25–34.
21.
Liebler DC. The role of metabolism in the antioxidant function of vitamin E. Crit Rev Toxicol. 1993;23:147–69.
22.
Palace VP, Hill MF, Farahmand F, Singal PK. Mobilization of antioxidant vitamin pools and hemodynamic function after myocardial infarction. Circulation. 1999;99:121–6.
23.
Reimann MJ, Häggström J, Møller JE, Lykkesfeldt J, Falk T, Olsen LH. Markers of oxidative stress in dogs with myxomatous mitral valve disease are influenced by sex, neuter status, and serum cholesterol concentration. J Vet Intern Med. 2017;31:295–302.
24.
Boisset S, Steghens J-P, Favetta P, Terreux R, Guitton J. Relative antioxidant capacities of propofol and its main metabolites. Arch Toxicol. 2004;78:635–42.
25.
Rigobello MP, Stevanato R, Momo F, Fabris S, Scutari G, Boscolo R, et al. Evaluation of the antioxidant properties of propofol and its nitrosoderivative. Comparison with homologue substituted phenols. Free Radic Res. 2004;38:315–21.
26.
Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A, et al. Propofol: A review of its non-anaesthetic effects. Eur J Pharmacol. 2009;605:1–8.
27.
Hans P, Deby-Dupont G, Deby C, Pieron F, Verbesselt R, Franssen C, Lamy M. Increase in antioxidant capacity of plasma during propofol anesthesia. J Neurosurg Anesthesiol. 1997;9:234–6.
28.
Stratford N, Murphy P. Antioxidant activity of propofol in blood from anaesthetized patients. Eur J Anaesthesiol. 1998;15:158–60.
29.
Popov IN, Lewin G. Photochemiluminescent detection of antiradical activity: II. Testing of nonenzymic water-soluble antioxidants. Free Radic Biol Med. 1994;17:267–71.
30.
Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000;29:1106–14.
31.
Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23:1142–50.
32.
Pinheiro J, Bates D, DebRoy S, Sarkar D, Development Core Team R. R. nlme: linear and nonlinear mixed effects models 2015. R Package version 3.1–142 R package, 1–3. Available from:
https://cran.r-project.org/web/packages/nlme/nlme.pdf
.